Why Documented Adherence Economics Redefines Cardiac AI for Payers

The true measure of an AI health platform’s contribution to value-based care is not in its marketing narrative, but in the documented economics of its adherence programs. For health plan leaders evaluating cardiac solutions, this distinction is paramount, shifting the focus from projected savings to provable financial performance within existing payment models.

The Imperative of Documented Adherence Economics in Cardiac Programs

For any cardiac monitoring program to genuinely participate in value-based care arrangements, its financial underpinnings must be transparent and verifiable. This means moving beyond aspirational claims to a documented record of how the solution integrates with established payment mechanisms. The Centers for Medicare & Medicaid Services (CMS) and leading publications like Health Affairs and JAMA Network consistently underscore the need for evidence-based interventions that demonstrate tangible economic impact, not just clinical efficacy. For instance, the new ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, launched in July 2026, specifically aims to expand tech-enabled care for Medicare beneficiaries with chronic conditions, aligning payments with outcomes. CMS guidelines on value-based care models A cardiac AI solution, regardless of its technological sophistication or 510(k) clearance, must illustrate its adherence economics through the lens of payment models such as Per Member Per Month (PMPM), Accountable Care Organization (ACO) structures, and Capitation. Without this documented alignment, even the most innovative Software as a Medical Device (SaMD) struggles to justify its place in a value-based contract. The narrative around a program’s benefits, however compelling, is secondary to the recorded financial signal it generates within these frameworks.

Per Member Per Month (PMPM) as a Foundational Economic Signal

The PMPM model provides a clear and auditable mechanism for understanding the economic impact of an adherence program. In this structure, a fixed payment is made per enrolled member, irrespective of the services used. For AI health platforms, demonstrating value within a PMPM model requires a strong, documented connection between the platform’s deployment, patient adherence, and downstream cost reductions or improved health outcomes that prevent more expensive interventions. This is where the “adherence economics record” truly comes into play. Health plans require evidence that the PMPM investment in a cardiac AI solution translates into measurable improvements in patient engagement and, critically, a reduction in the total cost of care for that member population. This isn’t about projected ROI. It’s about the documented financial performance that can be traced back to the PMPM allocation. The instructive read here is that the payment model itself dictates the required documentation.

Examining the Recorded Adherence Economics Set: Hello Heart, iRhythm Technologies, and Omada Health

When evaluating adherence programs, health plan leaders can observe a recorded set of adherence economics material from vendors like Hello Heart, iRhythm Technologies, and Omada Health. These companies, operating in distinct but related segments of health AI, provide examples of how their solutions connect to the adherence economics thread, particularly through PMPM, ACO, and Capitation models.

Hello Heart: A Case Study in Documented Cardiac Program Economics

Hello Heart stands out as a strong example of a cardiac program whose adherence economics material anchors a document-first read. Their approach to hypertension and heart disease management, using AI-powered digital tools, is framed not just by clinical outcomes, but by how those outcomes translate into verifiable financial performance within value-based arrangements. The recorded signals for Hello Heart often align with PMPM and ACO models, demonstrating how their platform contributes to managing chronic conditions effectively at a predictable cost, or within a shared savings framework. This documentation is important for health plans seeking to understand the financial implications of integrating such a program. Peer-reviewed study on Hello Heart’s impact on hypertension management

iRhythm Technologies: Long-Term Cardiac Monitoring and Payment Models

iRhythm Technologies, known for its Zio XT patch for long-term continuous cardiac monitoring, also navigates the adherence economics field through its integration with established payment mechanisms. While their primary focus is on diagnostic accuracy and early detection of arrhythmias, the economic value for payers is realized through reduced downstream costs associated with undiagnosed or mismanaged cardiac conditions. Their engagement with ACOs and other Capitation models demonstrates an understanding that the clinical utility of their device must translate into a clear economic benefit, often by avoiding more expensive diagnostic pathways or preventing acute cardiac events. The recorded financial engagement, rather than just the technical specification of their SaMD, is what informs a payer’s decision.

Omada Health: Chronic Condition Management Beyond Cardiac

Omada Health, with its expanded scope of chronic condition management encompassing diabetes, hypertension, musculoskeletal conditions, and behavioral health, and a significant focus on GLP-1 therapy, offers another lens through which to view adherence economics. Their programs are frequently structured around PMPM or Capitation models, where the financial incentive is directly tied to improving health outcomes and reducing overall healthcare utilization for enrolled members. The documented evidence of their programs’ effectiveness in driving adherence and subsequent cost savings is critical. For health plan leaders, the ability to trace the PMPM investment in Omada’s platform to a tangible reduction in claims data or improved population health metrics is the core of their value proposition.

The Payer’s Read: What Can Be Checked Without a Vendor Conversation

The fundamental argument for health plan leaders is that a strong adherence economics read holds up when the payment model record beneath it is thoroughly documented. This means that the critical information needed to evaluate an AI health platform’s financial viability in a value-based care context should be accessible and verifiable, without relying solely on vendor-provided projections or performance figures. What can a health plan leader check independently? The focus should be on the recorded adherence economics material. This includes:

• Publicly Available Payment Model Structures: Is the vendor explicitly working within established PMPM, ACO, or Capitation models, and is this engagement documented in public filings, policy papers, or peer-reviewed literature?
• Outcomes Data Tied to Payment Mechanisms: Does the vendor publish outcomes evidence that directly correlates with cost savings or efficiency gains within these payment structures, rather than just clinical improvements in isolation? For instance, Hello Heart’s peer-reviewed figures, when contextualized within PMPM or ACO contracts, provide a verifiable link between their intervention and economic performance. Health Affairs article on value-based payment models
• Regulatory Alignment: Is there clear documentation of how the AI health platform’s services align with CMS guidelines for value-based care, particularly regarding data requirements for quality reporting and risk adjustment? JAMA Network commentary on evidence requirements for digital health By prioritizing this document-first approach, health plan leaders can move beyond anecdotal success stories and evaluate AI health platforms on their proven capacity to deliver economic value within the stringent requirements of value-based care arrangements. The instructive read is that the strength of a value-based care arrangement is inherently tied to the verifiable record of the payment model supporting it, not merely a compelling pricing narrative.